Quidel has developed an innovative line of respiratory products for decades.


So whatever respiratory season may bring, we’re ready. 1979


Quidel founded


2015 1999


Receives FDA clearance for world’s fi rst rapid diagnostic fl u test QuickVue Infl uenza Test (A/B)


Introduction of Solana assays


2020 2011 1996


Quidel launches Sofi a automated analyzer FIA


First company to receive CLIA waiver for Strep A with QuickVue In-Line Strep A Test


2018


Receives FDA clearance for QuickVue Infl uenza A+B which meets FDA’s Class II RIDT requirements


Receives FDA EUA for Sofi a 2 SARS Antigen FIA, Sofi a 2 Flu+SARS FIA (ABC), QuickVue SARS Antigen Test, and Solana SARS-CoV-2


QuickVue® Infl uenza A+B, RSV, SARS*


Antigen Assays


Solana® Infl uenza A+B, RSV + hMPV, SARS-CoV-2*


, Bordetella Complete Assays


Sofi a®


/Sofi a 2


Infl uenza A+B, RSV, SARS* Antigen, Flu + SARS* Antigen Assays


To get the right RIDT for your patient, contact a Quidel Inside Sales at 858.431.5814 or visit quidel.com


*THESE TESTS ARE AVAILABLE FOR SALE IN THE USA UNDER EMERGENCY USE AUTHORIZATION. These SARS tests have not been FDA cleared or approved, but have been authorized by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories for the detection of proteins (QuickVue and Sofi a) or nucleic acids (Solana) from SARS-CoV-2, not for any other viruses or pathogens. These tests are only authorized for the duration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless terminated or revoked sooner.


AD10183600EN00 (06/22)

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52